Publisher
Norwegian Medical Association
Reference5 articles.
1. Gjerden P. Unyttige psykofarmakologiske analyser. Dagens Medisin. 18.9.2009. https://www.dagensmedisin.no/artikler/2009/09/18/unyttige-psykofarmakologiske-analyser/?x=MjAxNy0wMi0wNSAwMjoyNzowNA==&x=MjAxNy0wMi0wNSAwMjoyNzowNA== Lest 25.10.2022.
2. Solhaug V, Haslemo T, Kringen MK et al. Genotyping av pasienter behandlet med selektive serotoninreopptakshemmere. Tidsskr Nor Legeforen 2022; 142. doi: 10.4045/tidsskr.22.0017. [PubMed][CrossRef]
3. Jukić MM, Haslemo T, Molden E et al. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. Am J Psychiatry 2018; 175: 463–70. [PubMed][CrossRef]
4. Frederiksen T, Smith RL, Jukic MM et al. Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients. J Clin Psychopharmacol 2022; 42: 396–9. [PubMed][CrossRef]
5. Smith RL, Tveito M, Kyllesø L et al. Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders. Schizophr Res 2021; 228: 590–6. [PubMed][CrossRef]